Autoimmune Hepatitis Pipeline

DelveInsight’s, “Autoimmune Hepatitis Pipeline Insight, 2026” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Autoimmune Hepatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Autoimmune Hepatitis Understanding

Autoimmune Hepatitis Overview

Autoimmune hepatitis is a condition where the liver undergoes long-term inflammation, but the exact cause is uncertain. It's believed to stem from a combination of genetic predisposition, environmental factors, and immune system malfunction. This leads to ongoing inflammation of liver cells and eventual scarring of the liver tissue. There are two main types: Type 1, characterized by anti-smooth muscle antibodies (ASMA) possibly accompanied by anti-nuclear antibodies (ANA), and Type 2, marked by the presence of anti-liver/anti-kidney microsome (anti-LMK) type 1 antibodies or anti-liver cytosol (anti-LC) type 1 antibodies.

Autoimmune hepatitis is characterized by hypergammaglobulinemia, circulating autoantibodies, and interface hepatitis on liver histology, with a favorable response to immunosuppression. The histological features include a chronic hepatitis pattern with mild to moderate lymphocytic inflammation in the portal tracts, rich in plasma cells, and interface activity, along with intact native bile ducts and minimal lobular inflammation. Trichrome staining typically reveals no significant increase in fibrosis. A liver biopsy is crucial for diagnosis, as the histologic findings differentiate AIH from other liver conditions, although correlation with clinical and laboratory data is necessary due to potential overlap with viral hepatitis or drug-induced liver injury.

Autoimmune hepatitis can manifest with a variety of signs and symptoms, ranging from mild to severe. Common symptoms include fatigue, abdominal discomfort or pain, jaundice, dark urine, pale stools, loss of appetite, nausea, and unintended weight loss. Some individuals may experience joint pain, itching, and skin rashes. In severe cases, autoimmune hepatitis can lead to complications such as cirrhosis, which can cause additional symptoms like fluid retention in the abdomen (ascites), confusion, easy bruising or bleeding, and swelling in the legs. Treatment for autoimmune hepatitis involve initiating therapy in patients meeting specific criteria, including significantly elevated liver enzymes, high gamma globulin levels, and specific histological findings on liver biopsy. Corticosteroids, particularly prednisone, are the mainstay of treatment, either as monotherapy or in combination with azathioprine, although budesonide may be used as an alternative to reduce side effects. Remission is achieved when symptoms resolve, inflammatory markers normalize, and liver histology improves. Regular monitoring is essential, as relapse can occur after discontinuing therapy, necessitating ongoing management to prevent cirrhosis development and monitor for hepatocellular carcinoma. Liver transplantation is considered for patients with fulminant hepatic failure or disease progression despite treatment.

"Autoimmune Hepatitis Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Autoimmune Hepatitis pipeline landscape is provided which includes the disease overview and Autoimmune Hepatitis treatment guidelines. The assessment part of the report embraces, in depth Autoimmune Hepatitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Autoimmune Hepatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Autoimmune Hepatitis Pipeline Report Highlights

The Autoimmune Hepatitis companies and academics are working to assess challenges and seek opportunities that could influence Autoimmune Hepatitis R&D. The therapies under development are focused on novel approaches to treat/improve Autoimmune Hepatitis.

Autoimmune Hepatitis Emerging Drugs Analysis

This segment of the Autoimmune Hepatitis report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Autoimmune Hepatitis Emerging Drugs

HR19042: Jiangsu Hengrui Medicine Co., Ltd.

HR19042 is an investigational, targeted-release oral budesonide formulation developed by Jiangsu Hengrui Medicine Co., Ltd. for immune-mediated diseases, particularly primary IgA nephropathy (IgAN) and autoimmune hepatitis (AIH). The capsule is designed to release budesonide specifically in the distal ileum, targeting gut-associated lymphoid tissue to reduce the production of pathogenic IgA antibodies while minimizing systemic corticosteroid exposure. In a Phase II/III study in patients with primary IgA nephropathy, HR19042 demonstrated significant reductions in proteinuria and slowed decline in kidney function, with a favorable safety and tolerability profile. The product has also been investigated for active autoimmune hepatitis, an area with substantial unmet need, and has received clinical trial approvals in China. HR19042 represents Hengrui's effort to develop a next-generation gut-targeted corticosteroid therapy for autoimmune and renal diseases. Currently, the drug is in Phase II for the treatment of autoimmune hepatitis.

PVT201: Parvus Therapeutics Inc.

PVT201 is an investigational antigen-specific immunotherapy being developed by Parvus Therapeutics using the company's proprietary Navacim™ nanoparticle platform. The therapy is designed to induce antigen-specific immune tolerance by reprogramming disease-causing T cells without broadly suppressing the immune system. PVT201 is being explored for autoimmune diseases, with an initial focus on conditions driven by aberrant immune responses. The approach aims to provide durable disease control while minimizing the safety risks associated with conventional systemic immunosuppressive therapies. The drug is currently in Phase I/II for autoimmune hepatitis.

Further product details are provided in the report……..

Autoimmune Hepatitis Drug Therapeutic Assessment

This segment of the report provides insights about the different Autoimmune Hepatitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Autoimmune Hepatitis Players in Autoimmune Hepatitis

There are approx. 5+ key companies which are developing the therapies for Autoimmune Hepatitis. The companies which have their Autoimmune Hepatitis drug candidates in the most advanced stage, i.e. Phase II include, Jiangsu Hengrui Medicine Co., Ltd.

Autoimmune Hepatitis Clinical Trial Phases

DelveInsight’s report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Autoimmune Hepatitis Drug Route of Administration

Autoimmune Hepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Autoimmune Hepatitis Product Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Autoimmune Hepatitis Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Autoimmune Hepatitis Clinical Trial Activities

The Autoimmune Hepatitis pipeline report provides insights into different Autoimmune Hepatitis clinical trials within Phase III, II, I, preclinical and discovery stage. It also analyses Autoimmune Hepatitis therapeutic drugs key players involved in developing key drugs.

Autoimmune Hepatitis Pipeline Development Activities

The Autoimmune Hepatitis clinical Trial analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Autoimmune Hepatitis drugs.

Autoimmune Hepatitis Pipeline Report Insights

• Autoimmune Hepatitis Pipeline Analysis
• Autoimmune Hepatitis Therapeutic Assessment
• Autoimmune Hepatitis Unmet Needs
• Impact of Autoimmune Hepatitis Drugs

Autoimmune Hepatitis Pipeline Report Assessment

• Autoimmune Hepatitis Pipeline Product Profiles
• Autoimmune Hepatitis Therapeutic Assessment
• Autoimmune Hepatitis Pipeline Assessment
• Autoimmune Hepatitis Inactive drugs assessment
• Autoimmune Hepatitis Market Unmet Needs

Key Questions Answered In The Autoimmune Hepatitis Pipeline Report:

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Autoimmune Hepatitis drugs?
• How many Autoimmune Hepatitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Autoimmune Hepatitis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Autoimmune Hepatitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Autoimmune Hepatitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Autoimmune Hepatitis Key Players

• Jiangsu Hengrui Medicine Co., Ltd.
• Parvus Therapeutics Inc.
• Amgen

Autoimmune Hepatitis Key Products

• HR19042
• PVT201
• Inebilizumab